Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001104659-26-067917
Filing Date
2026-05-29
Accepted
2026-05-29 08:30:23
Documents
3

Document Format Files

Seq Description Document Type Size
1 424B5 tm2615976d1_424b5.htm 424B5 468039
2 GRAPHIC tm2615976d1_424b5img001.jpg GRAPHIC 7256
3 GRAPHIC tm2615976d1_424b5img002.jpg GRAPHIC 3840
  Complete submission text file 0001104659-26-067917.txt   484794
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 424B5 | Act: 33 | File No.: 333-278340 | Film No.: 261039172
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)